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In tro duc ti on
For application in the detection of congenital 
hypothyroidism (CH), we recently described an algorithm for 
calculating a diagnostic threshold for thyroid stimulating 
hormone (TSH) that is specific to each analytical run (1). In
this previous report, we had  mentioned three cases of
hypothyroidism that were detected using this variable
threshold and which would not have been detected using
the conventional threshold of 10 mIU/L. Here we describe
one of these cases in greater detail.
Case Report 
In 2006, a neonatal screening blood spot taken from a
newborn boy at age 3 days, and analyzed in our laboratory 8
days later, was found to have an Auto dissociation- enhanced
lanthanide fluorescence immunoassay (DELFIA)-measured
TSH concentration of 8.3 mIU/L in a run for which the 
run-specific TSH threshold was 8.2 mlU/L.  Duplicate analyses
of a second aliquots from the same spot yielded 
values of 8.2 and 9.4 mIU/L in a run with a threshold of 8.6
ABS TRACT
We report a case of congenital hypothyroidism (CH) with neurological
and respiratory alterations due to a heterozygotic c.374-1G > A mutation
of TITF1/NKX2-1. The hypothyroidism was detected using a neonatal
screening protocol in which the thyroid stimulating hormone (TSH)
threshold is re-set each day on the basis of within-day variability and
between-day variation. In this case, the threshold on the day of the 
initial analysis was 8.2 mIU/L, and the measured TSH level in heel-prick
blood was 8.3 mIU/L.   
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mIU/L. A second  paper-borne sample was requested, taken
at age 18 days, and analyzed in duplicate upon arrival the
following day. Whole blood TSH levels of 57.3 and 66.9
mIU/L indicated hypothyroidism, and were corroborated by
analysis of a  conventional blood sample taken on the same
day which showed a serum TSH of 126 mIU/L (reference
range  0.35-5.50 mIU/L), a serum free thyroxine (fT4) of  0.75
ng/dL (reference range 0.08-1.87 ng/dL), a serum free 
triiodothyronine (fT3) of 3.55 pg/mL, and a serum thyroglobulin
(Tg) of  529.0 ng/mL. 
Thresholds are calculated in a spreadsheet with provision
for input of ancillary information, such as calibration line data,
that facilitates various analyses. 
At that stage (day 19), the child weighed 4410 g, 
measured 55.4 cm, and had a cranial circumference of 37.5
cm. The posterior fontanelle was lacking, the anterior 
measured 2x3 cm. Appearance of the face, muscle tone and
chest auscultation were normal, no abdominal hernia was
detected, and no jaundice was observed. Constipation during
the first few days of life was reported to have been treated
with an appropriate milk formula. Mother and child tested
negative for antithyroid antibodies. A diagnosis of CH was
made, and treatment with 14 µg/kg/day of levothyroxine
(Eutirox 25 µg) was begun the same day.   
The patient was the first child of non-consanguineous 
parents. The father measured 1.84 m, the mother (age at
menarche 17 years) 1.73 m. A brother of the mother had
been treated for euthyroid goitre when adolescent, but there
was no family history of mental retardation, deafness or
autoimmune disease.  
Gestation had been supervised, incident-free and 
drug-free, except for diazepam which  had been used for 
insomnia. No iodated antiseptics had been used. Birth was 
by spontaneous vertex delivery at term, with no use of 
povidone-iodine or other iodine-bearing compounds. The infant
weighed 3. 590 g (62.5th percentile) at birth, measured 52.0 cm
(82.5th percentile), and had an Apgar score of 9/10. During the
first day, he received oxygen for transitory tachypnoea of the
newborn. He was fed from birth with formula milk.
After 15 days of treatment, serum TSH concentration was
0.45 mIU/L and serum fT4 concentration 1.89 ng/dL. Progress
was monitored in accordance with the protocol of the Spanish
Society of Paediatric Endocrinology; levothyroxine dosage was
successively adjusted to maintain serum TSH <3 mIU/L and
serum fT4 >1.5 ng/dL. Between the initiation of treatment and
age 3 years, the greatest known deviation from these targets
was a serum TSH concentration of 8.64 mIU/L at age 6 months, 
accompanied by a serum fT4 concentration of 1.89 ng/dL.  
Up to age 3 years, the patient suffered numerous airway
infections (bronchiolitis), and following an eventual diagnosis
of bronchial hyperactivity, was treated with bronchodilators
and corticoid inhalants. At age 18 months, his tonsils and 
adenoids were removed.
During this period, progressive motor retardation was
detected. The patient was able to maintain an upright seated
position alone at age 10 months, stood alone at age 12 months,
and at age 16 months, walked with help, but with a very 
unstable gait and a broad walking base. At age 22 months, he
walked unaided, but with a broad walking base, frequent falls,
poor coordination; dystonia and mild general hypotonia were
observed. Intelligence quotient was normal at age 12 months,
and referential speech began at age 20 months.    
Evaluation of the motor retardation in the neuropaediatrics
service showed normal cranial MRI, electromyography and
karyotype findings.  In view of the general hypotonia of 
probable mixed central and peripheral origin and the absence
of teleangiectasies or altered ocular motility, treatment with
levodopa was begun, but was suspended upon the 
appearance of dyskinaesia.    
The diagnosis of hypothyroidism was reconfirmed at age 3
years: following the suspension of therapy, serum TSH 
rose to 50.9 mIU/L and fT4 fell to 0.95 ng/dL, while fT3 showed
little alteration at 3.87 pg/mL. Ultrasonography showed a 
thyroid of normal homogeneity and echogenicity but small size,
the right lobe measuring approximately 9x5x12 mm and the left
lobe 5x3x10 mm. 99mTc gammagraphy confirmed cervical 
location and showed no significant alteration of the right lobe
but virtually no contrast uptake in the left.
The combination of hypothyroidism, moderate respiratory
problems and motor control problems suggested the possibility
of  TITF1/NKX2-1 haploinsufficiency (2). A requested genetic
study revealed a heterozygotic c.374-1G >A mutation, resulting
in loss of the exon 2 splicing site and truncation of the protein.
Discussion
Hypothyroidism is the commonest paediatric endocrine 
disorder and the commonest cause of preventable mental
retardation. The incidence of CH is estimated as one per 3 000-
4 000 newborns (2,3). The most frequent aetiology of primary
congenital cases in Spain is thyroid ectopy (40.3%), followed by
thyroid agenesis (36.7%), dyshormonogenesis (11.8%) and
hypoplasia (3.4%) (4). Though mostly sporadic, thyroid 
dysgenesis (ectopy, agenesis and hypoplasia) is attributed to
alteration of the constitution or function of genes involved in
thyroid development (4). In 3-4% of cases, the gene affected
encodes one of the four transcription factors, the joint presence
of which defines thyroid follicular cells and their precursors from
the very beginning of thyroid morphogenesis: TITF1/NKX2-1,
TITF2/FOXE1, PAX8 or HHEX (4,5,6). Since in the normal indi-
vidual none of these factors is exclusive to the thyroid, 
extrathyroidal alterations arise in hereditary cases (7,8,9).
The gene for TITF1/NKX2-1 is located on chromosome 14
in locus q13 in the thyrocytes of the healthy developed 
thyroid, this protein regulates the genes for Tg and 
thyroperoxidase (both involved in T4 synthesis) by binding totheir promoter regions. It also plays crucial developmental and
functional roles in the brain and lung. In the lung, it controls
the expression of surfactant proteins and the morphogenic
protein Bmp4, among others (10), while in the brain, it is
essential for the formation of the basal ganglia, the migration
of GABA neurons to the cortex, and other processes (11,12).
Accordingly, most reported cases of haploinsufficient patients
with heterozygous mutation have involved mild thyroid 
dysfunction together with both neonatal respiratory difficulties
and choreoathetosis (13,14,15,16,17), although the precise
combination of symptoms can depend on the specific 
mutation. In one report, a heterozygotic 825delC defect 
gave rise to hypothyroidism and choreoathetosis but no 
respiratory distress (18). There have been no reports of
humans with mutations of both alleles, and it is assumed that
like the corresponding mouse models they must die at birth
due to pulmonary and/or cerebral defects (5). The fact that in
our patient the left thyroid lobe was present but failed to take
up contrast suggests that initial morphogenesis was followed
by failure of the thyrocytes of that side to differentiate.
The TSH threshold used in screening for CH differs 
widely among screening centres; the sixteen UK centres, for
example, use thresholds ranging from 5 to 12 mIU/L (blood)
(19,20), while in the twenty Spanish centres, the threshold is 10
mIU/L (blood). The threshold issue continues to generate 
considerable debate. Prematurity problems aside, the choice
of a threshold depends on the time post partum at which 
samples are taken, and on screening test technology.
Additionally, fears have been expressed that cut-offs as low as
5-10 mIU/L may result in overdiagnosis (21). This criticism
seems to overlook several facts: firstly, that a screening test is
not a diagnosis; secondly, that a properly handled recall should
not throw parents into a state of permanent anxiety, but leave
them happy for the extra trouble that is being taken; thirdly,
that although moderately depressed, T4 levels may not have
the disastrous consequences of classical CH, they are 
unlikely to be innocuous (22,23); and fourthly, that the lower
thresholds currently employed do allow the detection of more
cases of classical CH at an acceptable cost in increased recall
(20,24). In the present case, moreover, it is possible that the
hypothyroid/hypotonic/pulmonary syndrome affecting our
patient would not have been identified as soon as it was if
hypothyroidism had not initially been detected following a 
positive screening TSH level of 8.3 mIU/L. Nevertheless, more
precise information on the natural history of children with
neonatal TSH values in the 5-10 mIU/L range, and on normal
ranges of thyroid parameters on a time scale of 24 hours or
less, would certainly be welcome (21,24). Lott and coworkers
reported central 95% TSH ranges of 0.26-17.1 mIU/L (serum)
between 48 and 71 hours post partum, and 0-14.6 mIU/L
(serum) between 72 and 95 hours post partum (25).  
As noted above, screening thresholds depend on 
technology. The TSH threshold was set to 8 mIU/L in Scotland
when the DELFIA was introduced (26), and to 5 mIU/L in
Wales when the AutoDELFIA method was introduced (19). 
A technical parameter that has previously been taken into
account in setting T4 thresholds (see, e.g.), Kempers et al (27),
but not TSH thresholds, is within-day variation. Our variable
threshold algorithm takes into account both within-day 
variability and between-day variation in accuracy.
Taking samples at age 5-8 days, as in the UK, is 
preferable to age 3 days for discrimination between normal
infants and those with CH on the basis of TSH measurements,
which during this period fall in the former and rise in the latter. If
to increase sensitivity still further the default threshold of our
algorithm is set to 8 or 9 mIU/L instead of the 10 mIU/L we 
currently employ, there will be days on which the threshold used
nears the 6 mIU/L recommended by Korada and coworkers (20).
In conclusion, patients with CH associated with respiratory
pathology and choreoathetosis, ataxia or motor retardation
should arouse suspicion of an altered TITF1/NKX2-1 gene. 
In the case discussed here, the use of a TSH screening
threshold of just 8.2 mIU/L (whole blood), established by
means of our variable threshold algorithm1, allowed 
detection of CH in a patient with a heel-prick TSH level lower
than the conventional 10 mIU/L threshold used  worldwide.
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